Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
ApexOnco Front Page
Recent articles
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The company’s AN9025 will shortly enter phase 1.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
A more comprehensive dataset on JANX007 sends the group’s stock down.
But the group still hopes to get IGV-001 approved based on overall survival data.
